# Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

> **NCT03610724** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel
- **DRUG:** lymphodepleting chemotherapy
- **DRUG:** Bridging Therapy

## Key facts

- **NCT ID:** NCT03610724
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2021-07-27
- **Final completion:** 2023-04-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610724, "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03610724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*